Takeaways from PTAB’s Precedential Decision on Prior Art Analysis for Post-AIA Patents – IPWatchdog.com
Takeaways from PTAB’s Precedential Decision on Prior Art Analysis for Post-AIA Patents IPWatchdog.com
Archive for December, 2023
-
In: PATENT NEWS
-
In: COPYRIGHT NEWS
Swiss Digital Licensing Org Targets Twitter for Copyright Infringement – Billboard
Swiss Digital Licensing Org Targets Twitter for Copyright Infringement Billboard
-
In: PATENT NEWS
Brazilian Supreme Court issues new guidance on landmark patent term adjustment decision – IAM
Brazilian Supreme Court issues new guidance on landmark patent term adjustment decision IAM
-
In: COPYRIGHT NEWS
Artists aim to thwart AI with data-poisoning software and legal action – Cointelegraph
Artists aim to thwart AI with data-poisoning software and legal action Cointelegraph
-
In: PATENT NEWS
Guyanese Thelma Liverpool develops patented device to better care for elderly, bedridden patients – Caribbean Life – Caribbean Life
Guyanese Thelma Liverpool develops patented device to better care for elderly, bedridden patients – Caribbean Life Caribbean Life
-
In: PATENT NEWS
Access Advance Announces Major Additions to its HEVC and VVC Patent Pools – Business Wire
Access Advance Announces Major Additions to its HEVC and VVC Patent Pools Business Wire
-
In: COPYRIGHT NEWS
7 Critical Copyright And AI Questions Courts Need To Address – Law360
7 Critical Copyright And AI Questions Courts Need To Address Law360
-
In: PATENT NEWS
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program – Business Wire
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program Business Wire
-
In: PATENT NEWS
Right-to-repair bills push chief IP offers to adjust patent strategies in Canada – IAM
Right-to-repair bills push chief IP offers to adjust patent strategies in Canada IAM
-
In: PATENT NEWS
Daiichi Sankyo unit claims $182m in Novartis patent dispute – pharmaphorum
Daiichi Sankyo unit claims $182m in Novartis patent dispute pharmaphorum